Snapshot from Aug 13, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Regeneron Securities Class Action Filed
Regulatory class action

Regeneron Securities Class Action Filed

Analysis based on 6 articles · First reported Aug 06, 2026 · Last updated Aug 12, 2026

Sentiment
-30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit could negatively affect Regeneron's stock price due to potential legal costs and reputational damage. However, the impact is likely limited as the allegations relate to a single clinical trial and the company's overall financial health remains strong.

Pharmaceuticals Legal Services
Event Summary

Bronstein, Gewirtz & Grossman, LLC, LLC announced that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. and certain of its officers. The lawsuit alleges violations of federal securities laws during the Class Period from August 1, 2025 to May 15, 2026. The complaint claims that Regeneron made materially false and misleading statements regarding its Phase III Fianlimab-Libtayo study, including flawed statistical assumptions, lack of clinical differentiation, and low likelihood of achieving statistical significance. Investors who purchased Regeneron securities during the Class Period are encouraged to join the case, with a lead plaintiff deadline of September 14, 2026.

Key Actions
100 Bronstein, Gewirtz & Grossman, LLC filed class action Regeneron Pharmaceuticals
Entities Involved
stock
Regeneron Pharmaceuticals
Regeneron is the defendant in the class action lawsuit, facing allegations of securities fraud related to its Phase III Fianlimab-Libtayo study. The lawsuit could result in financial penalties and damage to its reputation, though the company continues to operate normally.
Importance 100.0 Sentiment -40.0
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is the law firm representing the class action plaintiffs. The firm stands to gain from successful litigation, potentially earning contingency fees, and its involvement highlights its active role in investor protection.
Importance 80.0 Sentiment 20.0
per
Peretz Bronstein
Peretz Bronstein is the founding partner of the law firm and is listed as a contact for the class action. His role is to lead the legal effort on behalf of investors, which could enhance his firm's reputation.
Importance 30.0 Sentiment 10.0
per
Nathan Miller
Nathan Miller is the Client Relations Manager at the law firm and serves as a contact for investors. His involvement is administrative, supporting the class action process.
Importance 20.0 Sentiment 5.0
Relationships
Bronstein, Gewirtz & Grossman, LLC related ↔ Peretz Bronstein
Bronstein, Gewirtz & Grossman, LLC related ↔ Nathan Miller
Peretz Bronstein principal ↔ Nathan Miller Peretz Bronstein is the founding partner of Bronstein, Gewirtz & Grossman, LLC, and acts as a principal for Nathan Mille
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.